Canada approves GSK's Hibsago for chronic hepatitis B
GSK•Health Canada approved GSK's Hibsago as Canada's first finite therapy indicated to achieve functional cure in eligible adults with chronic hepatitis B; supply is expected in early 2027.
1. Canadian approval
Health Canada approved GSK's Hibsago (bepirovirsen) as Canada's first finite therapy indicated to achieve functional cure in eligible adults with chronic hepatitis B. Supply for eligible patients in Canada is expected in early 2027.
